Shanghai Junshi Biosciences Co Ltd
01877
Company Profile
Business description
Shanghai Junshi Biosciences Co Ltd is mainly engaged in innovation-driven biopharmaceutical business. The company's main products include teriprizumab injection, Etesevimab, adalimumab injection, and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases, and infectious diseases. The group’s operations are mainly located in the PRC and the United States of America.
Contact
No. 987 Cai Lun Road
Level 4, Pilot Free Trade Zone
Shanghai
CHNT: +86 2161058800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2,578
Stocks News & Analysis
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,003.50 | 11.90 | -0.13% |
| CAC 40 | 7,861.96 | 4.60 | 0.06% |
| DAX 40 | 24,262.22 | 44.85 | 0.19% |
| Dow JONES (US) | 44,461.28 | 171.71 | -0.38% |
| FTSE 100 | 9,136.94 | 0.62 | 0.01% |
| HKSE | 24,906.39 | 270.54 | -1.07% |
| NASDAQ | 21,129.67 | 31.38 | 0.15% |
| Nikkei 225 | 41,020.79 | 366.09 | 0.90% |
| NZX 50 Index | 12,836.39 | 19.58 | -0.15% |
| S&P 500 | 6,362.90 | 7.96 | -0.12% |
| S&P/ASX 200 | 8,749.30 | 7.10 | -0.08% |
| SSE Composite Index | 3,591.26 | 24.46 | -0.68% |